Skip to main content

Table 5 Post-operative primary and secondary outcomes

From: Is there a renoprotective value to leukodepletion during heart valve surgery? A randomized controlled trial (ROLO)

  

Randomized to leukodepletion filter

(n = 32)

Randomized to standard filter

(n = 31)

Overall (n = 63)

n

%

n

%

n

%

(95% CI)

PRIMARY OUTCOME:

 Any AKI

At any time

14/32

44%

7/31

23%

21/63

33%

(0.22, 0.46)

Prior to discharge

14/29

48%

6/25

24%

20/54

37%

 

Between discharge and 6 weeks ~

0/26

0%

1/24

4%

1/50

2%

 

 Highest AKI stage

Stage 1

9/14

64%

4/6

67%

13/20

65%

 

Stage 2

4/14

29%

1/6

17%

5/20

25%

 

Stage 3

1/14

7%

1/6

17%

2/20

10%

 

 First instance of AKI

Day 1

9/14

64%

2/6

33%

11/20

55%

 

Day 2

4/14

29%

3/6

50%

7/20

35%

 

Day 3 to discharge

1/14

7%

1/6

17%

2/20

10%

 

 Maximum AKI stage

Day 1

6/14

43%

0/6

0%

6/20

30%

 

Day 2

7/14

50%

5/6

83%

12/20

60%

 

Day 3 to discharge

1/14

7%

1/6

17%

2/20

10%

 

SECONDARY OUTCOMES:

 Need for haemodialysis

1/32

3%

0/31

0%

1/63

2%

(0.0,0.1)

 In hospital mortality

2/32

6%

0/31

0%

2/63

3%

(0.0,0.1)

 Infection complications

5/32

16%

4/31

13%

9/63

14%

(0.1,0.3)

Length of post-operative stay

Median (IQR) days

7.7

(5.8, 13.9)

8.8

(5.9, 11.7)

7.9

(5.9, 12.0)

 

CICU length of stay

Median (IQR) days

47.3

(24.8, 100.0)

48.5

(26.6, 92.8)

48.5

(25.0, 98.3)

 

Ward length of stay

Median (IQR) days

120.8

(94.0, 168.8)

141.5

(92.0, 188.4)

121.3

(93.5, 187.0)

Â